Lorlatinib Induced Non-cardiogenic Pulmonary Edema.

IF 1 4区医学 Q3 MEDICINE, GENERAL & INTERNAL

Internal Medicine Pub Date : 2025-11-01 Epub Date: 2025-04-26 DOI:10.2169/internalmedicine.5156-24

Suzuka Matsuoka, Hiromi Watanabe, Tomoyoshi Inoue, Yuki Takigawa, Kenichiro Kudo, Akiko Sato, Ken Sato, Keiichi Fujiwara, Takuo Shibayama

引用次数: 0

Abstract

A 71-year-old woman was diagnosed with anaplastic lymphoma kinase-positive metastatic lung adenocarcinoma staged as cT1cN3M1c (8th edition). Treatment with lorlatinib (100 mg) was initiated on a daily basis. Three weeks after the first dose, the patient was hospitalized because of lorlatinib-induced noncardiogenic pulmonary edema. The patient's condition improved with diuretic therapy, and lorlatinib was rechallenged at a reduced dose. Follow-up computed tomography revealed a partial response. This is a rare case of non-cardiogenic pulmonary edema as an adverse effect of lorlatinib.

Abstract Image

查看原文本刊更多论文

氯拉替尼致非心源性肺水肿1例报告。

一名71岁女性被诊断为间变性淋巴瘤激酶（ALK）阳性转移性肺腺癌，分期为cT1cN3M1c（第8版）。lorlatinib （100mg）每日开始治疗。第一次给药后3周，患者因氯拉替尼诱导的非心源性肺水肿住院。患者的病情在利尿剂治疗后得到改善，并再次使用了降低剂量的氯拉替尼。后续计算机断层扫描显示部分反应。这是一个罕见的病例非心源性肺水肿作为不良反应的氯拉替尼。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Internal Medicine 医学-医学：内科

CiteScore

1.90

自引率

8.30%

发文量

审稿时长

2.2 months

期刊介绍： Internal Medicine is an open-access online only journal published monthly by the Japanese Society of Internal Medicine. Articles must be prepared in accordance with "The Uniform Requirements for Manuscripts Submitted to Biomedical Journals (see Annals of Internal Medicine 108: 258-265, 1988), must be contributed solely to the Internal Medicine, and become the property of the Japanese Society of Internal Medicine. Statements contained therein are the responsibility of the author(s). The Society reserves copyright and renewal on all published material and such material may not be reproduced in any form without the written permission of the Society.